Advanced search
Publication Cover
Clinical Ophthalmology Volume 14, 2020 - Issue
Submit an article Journal homepage
295
Views
9
CrossRef citations to date
0
Altmetric
Rapid Communication

Signs and Symptoms of Ocular Surface Disease: The Reasons for Patient Dissatisfaction with Glaucoma Treatments

Ingeborg Stalmans1 Department of Ophthalmology, UZ Leuven, Leuven, BelgiumView further author information
,
Hans Lemij2 Glaucoma Service, Rotterdam Eye Hospital, Rotterdam, the NetherlandsView further author information
,
Jonathan Clarke3 NIHR Biomedical Research Centre - Moorfields Eye Hospital, NHS Foundation Trust and UCL Institute of Ophthalmology, London, UKView further author information
,
Christophe Baudouin4 Ophthalmology Unit, Quinze-Vingts National Hospital and Vision Institute, IHU ForeSight, Sorbonne University, Paris, FranceCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-1743-6698View further author information
ORCID Icon & On behalf of the GOAL study group
Pages 3675-3680 | Published online: 30 Oct 2020

References

  • Ware JE, Snyder MK, Wright WR, Davies AR. Defining and measuring patient satisfaction with medical care. Eval Program Plann. 1983;6(3–4):247–263. doi:10.1016/0149-7189(83)90005-8
  • Kerr NM, Patel HY, Chew SS, Ali NQ, Eady EK, Danesh-Meyer HV. Patient satisfaction with topical ocular hypotensives. Clin Exp Ophthalmol. 2013;41(1):27–35. doi:10.1111/j.1442-9071.2012.02823.x
  • Day DG, Sharpe ED, Atkinson MJ, Stewart JA, Stewart WC. The clinical validity of the treatment satisfaction survey for intraocular pressure in ocular hypertensive and glaucoma patients. Eye (Lond). 2006;20(5):583–590. doi:10.1038/sj.eye.6701932
  • Sleath B, Robin AL, Covert D, Byrd JE, Tudor G, Svarstad B. Patient-reported behavior and problems in using glaucoma medications. Ophthalmology. 2006;113(3):431–436. doi:10.1016/j.ophtha.2005.10.034
  • Sleath BL, Blalock SJ, Muir KW, et al. Determinants of self-reported barriers to glaucoma medicine administration and adherence: a multisite study. Ann Pharmacother. 2014;48(7):856–862. doi:10.1177/1060028014529413
  • Zimmerman TJ, Hahn SR, Gelb L, Tan H, Kim EE. The impact of ocular adverse effects in patients treated with topical prostaglandin analogs: changes in prescription patterns and patient persistence. J Ocul Pharmacol Ther. 2009;25(2):145–152. doi:10.1089/jop.2008.0072
  • Baudouin C, Labbe A, Liang H, Pauly A, Brignole-Baudouin F. Preservatives in eyedrops: the good, the bad and the ugly. Prog Retin Eye Res. 2010;29(4):312–334. doi:10.1016/j.preteyeres.2010.03.001
  • European Glaucoma Society. Terminology and guidelines for glaucoma, 4th edition - chapter 2: classification and terminology supported by the EGS foundation: part 1: foreword; introduction; glossary; chapter 2 classification and terminology. Br J Ophthalmol. 2017;101(5):73–127. doi:10.1136/bjophthalmol-2016-EGSguideline.002
  • European Glaucoma Society. Terminology and guidelines for glaucoma, 4th edition - chapter 3: treatment principles and options supported by the EGS foundation: part 1: foreword; introduction; glossary; chapter 3 treatment principles and options. Br J Ophthalmol. 2017;101(6):130–195.
  • European Glaucoma Society. Terminology and guidelines for glaucoma, 4th edition - part 1 supported by the EGS foundation. Br J Ophthalmol. 2017;101(4):1. doi:10.1136/bjophthalmol-2016-EGSguideline.001
  • Lemij HG, Hoevenaars JG, van der Windt C, Baudouin C. Patient satisfaction with glaucoma therapy: reality or myth? Clin Ophthalmol. 2015;9:785–793.
  • IEA. International epidemiological association: Good Epidemiological Practice (GEP), IEA guidelines for proper conduct in epidemiological research; 2007. Available from: http://ieaweb.org/good-epidemiological-practice-gep/. Accessed February 08, 2018.
  • Li F, Huang W, Zhang X. Efficacy and safety of different regimens for primary open-angle glaucoma or ocular hypertension: a systematic review and network meta-analysis. Acta Ophthalmol. 2018;96(3):e277–e84. doi:10.1111/aos.13568
  • Garcia-Feijoo J, Sampaolesi JR. A multicenter evaluation of ocular surface disease prevalence in patients with glaucoma. Clin Ophthalmol. 2012;6:441–446.
  • Fechtner RD, Godfrey DG, Budenz D, Stewart JA, Stewart WC, Jasek MC. Prevalence of ocular surface complaints in patients with glaucoma using topical intraocular pressure-lowering medications. Cornea. 2010;29(6):618–621. doi:10.1097/ICO.0b013e3181c325b2
  • Van Went C, Brasnu E, Hamard P, Baudouin C, Labbe A. [The influence of ocular surface diseases in the management of glaucoma]. J Fr Ophtalmol. 2011;34(4):230–237. French. doi:10.1016/j.jfo.2010.11.010
  • Leung EW, Medeiros FA, Weinreb RN. Prevalence of ocular surface disease in glaucoma patients. J Glaucoma. 2008;17(5):350–355.
  • Baudouin C, Renard JP, Nordmann JP, et al. Prevalence and risk factors for ocular surface disease among patients treated over the long term for glaucoma or ocular hypertension. Eur J Ophthalmol. 2013;23(1):47–54. doi:10.5301/ejo.5000181
  • Thygesen J. Glaucoma therapy: preservative-free for all? Clin Ophthalmol. 2018;12:707–717. doi:10.2147/OPTH.S150816
  • Economou MA, Laukeland HK, Grabska-Liberek I, Rouland JF. Better tolerance of preservative-free latanoprost compared to preserved glaucoma eye drops: the 12-month real-life FREE study. Clin Ophthalmol. 2018;12:2399–2407. doi:10.2147/OPTH.S176605

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.